Literature DB >> 8081453

Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria.

H Noack1, U Kube, W Augustin.   

Abstract

In order to evaluate different mitochondrial antioxidant systems, the depletion of alpha-tocopherol and the levels of the reduced and oxidized forms of CoQ were measured in rat liver mitochondria during Fe++/ascorbate and NADPH/ADP/Fe++ induced lipid peroxidation. During the induction phase of malondialdehyde formation, alpha-tocopherol declined moderately to about 80% of initial contents, whereas the total CoQ pool remained nearly unchanged, but reduced CoQ9 continuously declined. At the start of massive malondialdehyde formation, CoQ9 reaches its fully oxidized state. At the same time alpha-tocopherol starts to decline steeply, but never becomes fully exhausted in both experimental systems. Evidently the oxidation of the CoQ9 pool constitutes a prerequisite for the onset of massive lipid peroxidation in mitochondria and for the subsequent depletion of alpha-tocopherol. Trapping of the GSH by addition of dinitrochlorbenzene (a substrate of the GSH transferase), results in a moderate acceleration of lipid peroxidation, but alpha-tocopherol and ubiquinol levels remained unchanged when compared with the controls. Addition of succinate to GSH depleted mitochondria effectively suppressed MDA formation as well as alpha-tocopherol and ubiquinol depletion. The data support the assumption that the protective effect of respiratory substrates against lipid peroxidation in the absence of mitochondrial GSH is mediated by the regeneration of the lipid soluble antioxidants CoQ and alpha-tocopherol.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8081453     DOI: 10.3109/10715769409145637

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  14 in total

Review 1.  Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.

Authors:  M Flint Beal
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

2.  Coenzyme Q10 inhibits glutamate excitotoxicity and oxidative stress-mediated mitochondrial alteration in a mouse model of glaucoma.

Authors:  Dongwook Lee; Myoung Sup Shim; Keun-Young Kim; You Hyun Noh; Heemin Kim; Sang Yeop Kim; Robert N Weinreb; Won-Kyu Ju
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-18       Impact factor: 4.799

3.  Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects.

Authors:  R T Matthews; L Yang; S Browne; M Baik; M F Beal
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

4.  Role of endogenous and exogenous antioxidants in the defence against functional damage and lipid peroxidation in rat liver mitochondria.

Authors:  W Augustin; I Wiswedel; H Noack; T Reinheckel; O Reichelt
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

5.  Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.

Authors:  Robert J Ferrante; Ole A Andreassen; Alpaslan Dedeoglu; Kimberly L Ferrante; Bruce G Jenkins; Steven M Hersch; M Flint Beal
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

6.  Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease.

Authors:  Magali Dumont; Khatuna Kipiani; Fangmin Yu; Elizabeth Wille; Maya Katz; Noel Y Calingasan; Gunnar K Gouras; Michael T Lin; M Flint Beal
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

7.  Enhanced sensitivity of ubiquinone-deficient mutants of Saccharomyces cerevisiae to products of autoxidized polyunsaturated fatty acids.

Authors:  T Q Do; J R Schultz; C F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

8.  Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.

Authors:  Lichuan Yang; Noel Y Calingasan; Elizabeth J Wille; Kerry Cormier; Karen Smith; Robert J Ferrante; M Flint Beal
Journal:  J Neurochem       Date:  2009-03-28       Impact factor: 5.372

9.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

Review 10.  The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment.

Authors:  Anna Giménez-Palomo; Seetal Dodd; Gerard Anmella; Andre F Carvalho; Giselli Scaini; Joao Quevedo; Isabella Pacchiarotti; Eduard Vieta; Michael Berk
Journal:  Front Psychiatry       Date:  2021-07-06       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.